Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection.
Eleven pediatric patients, aged 1 to 10 years and with symptomatic human immunodeficiency virus infection, were treated with 6 or 10 mg of oral ribavirin per kg of body weight daily for 60 days. Safety and pharmacokinetic parameters were monitored; five children had comprehensive pharmacokinetic eva...
Na minha lista:
| Publicado no: | Antimicrob Agents Chemother |
|---|---|
| Principais autores: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Microbiology (ASM)
1993
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC187703/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8460922/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.37.3.532 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|